이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 심각한 습진으로 6 세에서 12 세 미만의 어린이에서 아크로 시티 닙이라는 약에 대한 연구

2026년 11월 10일 업데이트: Pfizer

16 주, 다기관, 중재 적, 3 단계, 무작위 화, 이중 맹검, 위약 대조, 병렬 그룹 연구는 중등도에서 중등도의 아토피 성 피부염을 가진 6 세에서 12 세 미만의 어린이의 효능 및 안전성 및 안전성을 조사합니다.

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Different questionnaires will be used to find out how the participant's eczema is doing during the research study. An electronic diary, which looks like a cellular phone, will be used to collect the questionnaire information and other research study-related information. It will also be used to remind participants to take the test medicine each day and to fill out the questionnaires. Participants will also be asked to wear something on their wrist that looks like a children's wristwatch so we can know when they are scratching their skin because of their atopic dermatitis. Laboratory tests, physical examinations and vital signs (height, weight, temperature, blood pressure and heart rate) will be conducted before and during the research study to monitor your child's health. Participants will need to come to the clinic for research study visits and at other times during the research study, the research study doctor or nurse will call the participants to find out the participant is doing.

연구 유형

중재적

등록 (실제)

151

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, 독일, 48149
        • Universitätsklinikum Münster
    • Saxony
      • Dresden, Saxony, 독일, 01307
        • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
      • Chihuahua City, 멕시코, 31238
        • Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)
    • Mexico City
      • Mexico City, Mexico City, 멕시코, 06720
        • Hospital Infantil de México Federico Gómez
    • Nuevo León
      • Monterrey, Nuevo León, 멕시코, 64718
        • Eukarya Pharmasite S.C.
    • Veracruz
      • Veracruz, Veracruz, 멕시코, 91900
        • Arke SMO S.A. de C.V.
    • Alabama
      • Birmingham, Alabama, 미국, 35244
        • Cahaba Dermatology & Skin Health Center, LLC
    • Arkansas
      • North Little Rock, Arkansas, 미국, 72117
        • Arkansas Research Trials
    • California
      • San Diego, California, 미국, 92123
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego, California, 미국, 92123
        • University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
    • Florida
      • Jacksonville, Florida, 미국, 32256
        • Solutions Through Advanced Research
    • Idaho
      • Meridian, Idaho, 미국, 83646
        • Ada West Research
    • Indiana
      • Indianapolis, Indiana, 미국, 46250
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis, Missouri, 미국, 63104
        • Saint Louis University - Department of Dermatology
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina - Department of Dermatology
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina - Walton Research Building
      • Greenville, South Carolina, 미국, 29607
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio, Texas, 미국, 78235
        • Texas Dermatology and Laser Specialists
      • Zaragoza, 스페인, 50009
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela, A Coruña [LA Coruña], 스페인, 15706
        • CHUS - Hospital Clinico Universitario
    • Barcelona [barcelona]
      • Granollers, Barcelona [barcelona], 스페인, 08402
        • Hospital General de Granollers
      • Fukuoka, 일본, 811-1394
        • Fukuoka National Hospital
      • Fukuoka, 일본, 819-0042
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 220-6208
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai, Osaka, 일본, 593-8324
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku, Tokyo, 일본, 157-0066
        • Sasamoto Children's Clinic
      • Shanghai, 중국, 200062
        • Shanghai Children's Hospital
      • Shanghai, 중국, 200092
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100045
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen, Guangdong, 중국, 518026
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha, Hunan, 중국, 410007
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330000
        • Dermatology Hospital of Jiangxi Province
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200040
        • Shanghai Children's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310009
        • Hangzhou Third People's Hospital
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-002
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, 폴란드, 20-573
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-625
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, 폴란드, 41-500
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
      • Katowice, Silesian Voivodeship, 폴란드, 40-611
        • Centrum Medyczne Angelius Provita
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, 폴란드, 90-436
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 폴란드, 27-400
        • Dermedic Jacek Zdybski
      • Pécs, 헝가리, 7622
        • University of Pecs
    • Baranya
      • Pécs, Baranya, 헝가리, 7632
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba, Bekes County, 헝가리, 5600
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged, Csongrád-csanád, 헝가리, 6720
        • Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika
    • Pest County
      • Budapest, Pest County, 헝가리, 1033
        • Clinexpert Kft.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria Children aged 6 to <12 years at the time of informed consent/assent.

• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Disease Characteristics:

Participants who meet all of the following AD criteria:

  • A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
  • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
  • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy

Other Inclusion Criteria:

Body weight ≥15 kg

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

Have any of the following medical conditions:

  • Infections:

    • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
    • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
    • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
    • Infection with HIV, hepatitis B, and/or hepatitis C
    • Evidence of active TB or inadequately treated latent TB.
  • Skin Conditions:

    - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

  • Other Conditions:

    • Documented history of skeletal dysplasia.
    • Documented history of retinal detachment.
    • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
    • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
    • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
    • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

Prior/Concomitant Therapy:

Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.

Prior/Concurrent Clinical Study Experience:

Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Abrocitinib

Abrocitinib administered as liquid oral suspension.

Abrocitinib administered as liquid oral suspension.

다른 이름들:
  • PF-04965842
위약 비교기: Matching Placebo

Placebo administered as liquid oral suspension.

Placebo administered as liquid oral suspension.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
기간: At week 12

The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
기간: At week 12

The difference in proportion of responders based on EASI-75 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline (CFB) in the Worst Itch Numerical Rating Scale (WI-NRS) at Week 2
기간: At week 2

The difference in mean CFB in WI-NRS total score at Week 2 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 2
Response based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12
기간: At week 12

The difference in proportion of responders based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving WI-NRS <2 at Week 12
기간: At week 12

The difference in proportion of responders based on achieving WI-NRS <2 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Pfizer CT.gov Call Center, Pfizer

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 7월 24일

기본 완료 (추정된)

2027년 5월 2일

연구 완료 (추정된)

2027년 5월 2일

연구 등록 날짜

최초 제출

2025년 1월 29일

QC 기준을 충족하는 최초 제출

2025년 1월 29일

처음 게시됨 (실제)

2025년 2월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • B7451023
  • 2023-509121-51-00 (레지스트리 식별자: CTIS (EU))
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .